Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease-Reference-Cited by-同舟云学术

Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease

Published:2006-01-01 Issue:1 Volume:83 Page:80-85
ISSN:0925-5710
Container-title:International Journal of Hematology
language:
Short-container-title:International Journal of Hematology

Author:

Takami Akiyoshi,Mochizuki Kanako,Okumura Hirokazu,Ito Satsuki,Suga Yukio,Yamazaki Hirohito,Yamazaki Masahide,Kondo Yukio,Asakura Hidesaku,Nakao Shinji

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://www.springerlink.com/index/pdf/10.1532/IJH97.05111

Reference32 articles.

1. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821-1828.

2. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant. 2000;26:985-991.

3. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:613-620.

4. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555-561.

5. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428-1435.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial;BMC Medicine;2024-02-27

2. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis;Frontiers in Immunology;2022-08-04

3. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation;Biology of Blood and Marrow Transplantation;2019-02

4. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT;Bone Marrow Transplantation;2018-12-07

5. Mesenchymal Stem Cells: The First Approved Stem Cell Drug in Japan;Journal of Hematopoietic Cell Transplantation;2017